Paradigm's CME/CE programs in the cardiology space include those on the topics of Acute Coronary Syndromes, Anticoagulation, Hypertension, Treatment and Prevention of Venous Thromboembolism, and Stroke Prevention in Nonvalvular Atrial Fibrillation.
CLINICAL PHARMACISTS AND CHRONIC HEART FAILURE: UNDERSTANDING THE ROLE OF NEW AND ESTABLISHED THERAPIES
This initiative will define chronic heart failure (CHF) with reduced ejection fraction (HFrEF or systolic HF) and will provide visual information and expert instruction to help clinical pharmacists differentiate between CHF/HFrEF and CHF with preserved ejection fraction (HFpEF, or diastolic heart failure). Faculty will review existing algorithms for the use of established cardiovascular drugs in treating CHF/HFrEF and describe the mechanisms of action, approved or proposed indications, and role of new and emerging agents in the treatment of CHF/HFrEF. The information presented will be vital to clinical pharmacists who are assuming an ever increasing role on the CHF treatment team.
SELECTING DUAL ORAL ANTIPLATELET THERAPY FOR PATIENTS WITH ACUTE CORONARY SYNDROME
This series of live, CME-certified in-hospital grand rounds described contemporary dual antiplatelet therapy guideline recommendations or patients with ACS undergoing intervention, explained data on these therapies in patients with ACS and diabetes and with STEMI. It was designed to educate hospital-based physicians specialists in cardiology, internal medicine, emergency medicine, critical care, hospital medicine, and residents and fellows who manage patients with ACS.
DUAL ORAL ANTIPLATELET THERAPY FOR ACS: IMPROVING STANDARDS OF CARE TO OPTIMIZE OUTCOMES
This live CME-certified symposium at the AHA Scientific Sessions 2014 was designed for cardiologists and interventional cardiologists, primary care physicians, hospitalists, fellows, PAs, NPs, and other healthcare providers caring for patients with ACS. It reviewed the latest guidelines for dual oral antiplatelet therapy for patients presenting with ACS and described recent data on these therapies in patients with UA/NSTEMI and STEMI.
Based on the live presentation, the CME/CE-certified enduring webinar is intended for cardiologists, interventional cardiologists, emergency department physicians, primary care physicians, hospitalists, fellows, PAs, NPs, and other healthcare professionals caring for or interested in the management of patients with ACS.
ACUTE CORONARY SYNDROMES: OPTIMIZING DUAL ORAL ANTIPLATELET THERAPY
This series of CME-certified grand rounds addresses the most current practice guidelines in the management of ACS, and focuses on a better understanding of existing and novel antiplatelet therapy. It was designed for cardiologists, interventional cardiologists, internists, emergency medicine physicians, critical care specialists, hospitalists, as well as residents, fellows, NPs, and PAs who manage patients with ACS.